1 line
3.1 KiB
JSON
1 line
3.1 KiB
JSON
{"acquired gene mutation": 18.8, "acute graft versus host disease": 9.83, "acute hepatic failure": 14.71, "acute myeloid leukaemia": 14.71, "acute promyelocytic leukaemia": 38.42, "agranulocytosis": 24.97, "anaemia": 3.34, "anti-muellerian hormone level decreased": 497.6, "aplastic anaemia": 8.85, "b-cell lymphoma": 13.1, "b-cell lymphoma recurrent": 133.23, "bacteraemia": 7.03, "blood follicle stimulating hormone increased": 128.29, "blood lactate dehydrogenase increased": 5.17, "blood luteinising hormone increased": 180.35, "bone marrow failure": 6.46, "bronchopulmonary aspergillosis": 4.9, "cardiac failure": 3.04, "cardiomyopathy": 9.96, "cardiotoxicity": 36.57, "central nervous system lymphoma": 35.71, "chemotherapy": 32.91, "clostridium difficile infection": 3.25, "congenital aplasia": 13.53, "cytopenia": 15.07, "diffuse large b-cell lymphoma": 27.07, "diffuse large b-cell lymphoma recurrent": 116.79, "diffuse large b-cell lymphoma refractory": 54.24, "dilated cardiomyopathy": 5.35, "disease progression": 8.2, "drug resistance": 2.4, "drug-induced liver injury": 2.07, "ejection fraction decreased": 5.73, "encephalopathy": 2.85, "epstein-barr virus infection reactivation": 29.92, "febrile bone marrow aplasia": 15.88, "febrile neutropenia": 40.25, "foetal exposure during pregnancy": 2.4, "follicular lymphoma": 55.16, "granulocyte count decreased": 46.05, "granulocytopenia": 34.11, "haematotoxicity": 6.66, "haemoglobin decreased": 2.88, "haemophagocytic lymphohistiocytosis": 3.77, "hepatic failure": 2.98, "hepatic function abnormal": 5.15, "hepatitis b": 20.75, "hepatitis b reactivation": 45.88, "hodgkin's disease recurrent": 140.78, "hormone level abnormal": 10.28, "immune-mediated adrenal insufficiency": 10.03, "inappropriate antidiuretic hormone secretion": 5.55, "infection": 3.08, "intentional product use issue": 2.46, "interstitial lung disease": 9.69, "left ventricular dysfunction": 7.0, "leukopenia": 9.39, "liver injury": 2.9, "lymphocyte count decreased": 5.27, "lymphoma": 3.14, "lymphopenia": 3.63, "mucosal inflammation": 6.32, "multiple organ dysfunction syndrome": 2.12, "myelodysplastic syndrome": 10.11, "myelosuppression": 49.95, "neoplasm progression": 4.19, "neuropathy peripheral": 3.18, "neutropenia": 8.94, "neutropenic sepsis": 19.37, "neutrophil count decreased": 25.59, "no adverse event": 3.13, "non-hodgkin's lymphoma": 10.47, "oestradiol decreased": 529.91, "off label use": 3.67, "pancytopenia": 8.41, "platelet count decreased": 5.93, "pleural effusion": 2.08, "pneumocystis jirovecii pneumonia": 17.94, "pneumonia": 2.69, "pneumonitis": 2.57, "premature baby": 6.38, "premature labour": 11.77, "product use in unapproved indication": 13.02, "progressive multifocal leukoencephalopathy": 14.42, "pulmonary toxicity": 5.78, "red blood cell count decreased": 3.27, "respiratory failure": 2.1, "second primary malignancy": 29.88, "sepsis": 5.07, "septic shock": 5.63, "stomatitis": 3.37, "therapy partial responder": 6.32, "thrombocytopenia": 3.77, "toxicity to various agents": 2.38, "transaminases increased": 2.69, "tumour lysis syndrome": 17.39, "venoocclusive liver disease": 9.73, "white blood cell count decreased": 19.5} |